New ECLIPSE study validates the accuracy of Shield.  See the data

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

Study demonstrates 83% sensitivity for detection of colorectal cancer with specificity of 90%


Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.